The acquisition aims to strengthen MRD leadership, enhance biopharma offerings, and create a comprehensive diagnostics portfolio. Financial terms include a $16.25/share offer, mostly in stock, with closing expected by early 2027. Integration and reimbursement milestones are key to realizing growth and margin targets.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.